Table 1 Patients’ characteristics
From: Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel
Characteristic | Total 31 (100%) | |
|---|---|---|
Age at infusion | ≤ 65 years | 16 (51.6%) |
> 65 years | 15 (48.4%) | |
Median [IQR] | 63 [61–76] | |
Diagnosis | DLBCL NOS | 18 (58.1%) |
HGBCL with MYC and BCL2 and/or BCL6 rearrangements | 2 (6.5%) | |
PMBCL | 1 (3.2%) | |
DLBCL transformed from indolent lymphomas | 8 (25.8%) | |
T cell histiocyte rich lymphoma | 1 (3.2%) | |
FL Grade 3b | 1 (3.2%) | |
Sex | Female | 14 (45.2%) |
Male | 17 (54.8%) | |
# of previous therapies | 1 | 12 (38.7%) |
2 | 6 (19.4%) | |
≥ 3 | 13 (41.9%) | |
Previous ASCT | No | 28 (90.3%) |
Yes | 3 (9.7%) | |
Bridging therapy | No | 7 (22.6%) |
Yes | 24 (77.4%) | |
ECOG grade | ≤ 1 | 28 (90.3%) |
> 1 | 3 (9.7%) | |
Status at last disease evaluation | CR | 8 (25.8%) |
PR | 12 (38.7%) | |
SD | 2 (6.5%) | |
PD | 9 (29.0%) | |
Bulky disease* at last evaluation | No | 29 (93.5%) |
Yes | 2 (6.5%) | |
LDH levels at liso-cel infusion | Normal | 20 (64.5%) |
Elevated | 11 (35.5%) | |
Platelet count at liso-cel infusion | ≥ 50 × 109/L | 30 (96.8%) |
< 50 × 109/L | 1 (3.2%) | |
TRANSCEND-001-NHL inclusion criteria (n = 19) | Yes | 16 (84.2%) |
No | 3 (15.8%) | |
TRANSFORM inclusion criteria (n = 12) | Yes | 8 (66.7%) |
No | 4 (33.3%) |